Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Published by: GlobalData

Published: Nov. 30, 2011 - 80 Pages


Table of Contents

1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Osteoarthritis Therapeutics -
Introduction
2.1 Overview
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.4 Risk Factors
2.5 Symptoms
2.6 Diagnosis of OA
2.6.1 Clinical History
2.6.2 Physical Examination
2.6.3 Diagnostic Imaging Techniques
2.7 Treatment
2.7.1 Non-Pharmacological Therapy
2.7.2 Pharmacological Therapy
2.7.3 Surgical Treatment
2.8 GlobalData Pipeline Report Guidance
3 Osteoarthritis Therapeutics - Market Characterization
3.1 Major Markets, Market Size (2005-2010)
3.2 Major Markets, Market Forecast (2010-2018)
3.3 OA Therapeutics Market Size (2005-2010) - The US
3.4 OA Therapeutics Market Forecast (2010-2018) - The US
3.5 OA Therapeutics Market Size (2005-2010) - The UK
3.6 OA Therapeutics Market Forecast (2010-2018) - The UK
3.7 OA Therapeutics Market Size (2005-2010) - France
3.8 OA Therapeutics Market Forecast (2010-2018) - France
3.9 OA Therapeutics Market Size (2005-2010) - Germany
3.10 OA Therapeutics Market Forecast (2010-2018) - Germany
3.11 OA Therapeutics Market Size (2005-2010) - Italy
3.12 OA Therapeutics Market Forecast (2010-2018) - Italy
3.13 OA Therapeutics Market Size (2005-2010) - Spain
3.14 OA Therapeutics Market Forecast (2010-2018) - Spain
3.15 OA Therapeutics Market Size (2005-2010) - Japan
3.16 OA Therapeutics Market Forecast (2010-2018) - Japan
3.17 Drivers and Barriers for the OA Therapeutics Market
3.17.1 Drivers for the OA Therapeutics Market
3.17.2 Barriers for the OA Therapeutics Market
3.18 Key Events Impacting the Future Market
3.19 Opportunity and Unmet Need
3.20 Key Takeaway
4 OA Therapeutics Market - Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Profiles of Commonly Used Products in the OA Therapeutics Market
4.2.1 5.2.1 Celebrex (celecoxib)
4.2.2 Cymbalta (duloxetine hydrochloride)
4.2.3 Hyalgan (sodium hyaluronate)
4.2.4 Nucynta (tapentadol)
4.2.5 Voltaren Gel (diclofenac sodium topical gel 1%)
4.3 Key Takeaway
5 OA Therapeutics Market - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 OA Therapeutics - Molecules in Pre-Registration
5.2.2 OA Therapeutics - Phase III Pipeline
5.2.3 OA Therapeutics - Phase II/III Pipeline
5.2.4 OA Therapeutics - Phase II Pipeline
5.2.5 OA Therapeutics - Phase I/II Pipeline
5.2.6 OA Therapeutics - Phase I Pipeline
5.2.7 OA Therapeutics - Preclinical Pipeline
5.2.8 OA Therapeutics - Discovery Pipeline
5.3 OA Pipeline by Mechanism of Action
5.4 OA Technology Trends Analytical Framework
5.5 OA Therapeutics - Promising Drugs under Clinical Development
5.6 Molecule Profile for Promising Drugs under Clinical Development
5.6.1 Cartistem
5.6.2 Civanex (civamide, zucapsaicin)
5.6.3 Strontium Chloride Hexahydrate (2PX)
5.6.4 Oral Salmon Calcitonin (SMC021)
5.6.5 BEMA Buprenorphine
5.6.6 IP 880 and IP 889
5.7 Key Takeaway
6 Osteoarthritis Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in OA Therapeutics Clinical Trials
7 Osteoarthritis Therapeutics - Strategic Assessment
7.1 Osteoarthritis Therapeutics - Implications for Future Market Competition
8 Osteoarthritis Therapeutics - Future Players in the Market
8.1
Introduction
8.1.1 BioDelivery Sciences International
8.1.2 Cephalon, Inc.
8.1.3 Iroko Pharmaceuticals, LLC
8.1.4 Novartis AG
8.1.5 SantoSolve AS
8.1.6 Winston Pharmaceuticals, Inc.
8.1.7 Other Companies in Osteoarthritis Therapeutics Market
9 OA Therapeutics - Licensing and Partnership Deals
10 Osteoarthritis Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
1.1 List of Tables
Table 1: Osteoarthritis - Prevalence, Major Markets, 2010
Table 2: Surgical Procedures for Osteoarthritis
Table 3: OA Therapeutics Market, Major Markets, Revenue ($bn), 2005 - 2010
Table 4: OA Therapeutics Market, Major Markets, Forecast ($bn), 2010 - 2018
Table 5: OA Therapeutics Market, The US, Revenue ($bn), 2005 - 2010
Table 6: OA Therapeutics Market, The US, Forecast ($bn), 2010 - 2018
Table 7: OA Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Table 8: OA Therapeutics Market, The UK, Forecast ($m), 2010 - 2018
Table 9: OA Therapeutics Market, France, Revenue ($m), 2005 - 2010
Table 10: OA Therapeutics Market, France, Forecast ($m), 2010 - 2018
Table 11: OA Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Table 12: OA Therapeutics Market, Germany, Forecast ($m), 2010 - 2018
Table 13: OA Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Table 14: OA Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Table 15: OA Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Table 16: OA Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Table 17: OA Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Table 18: OA Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Table 19: OA Therapeutics - Molecules in Pre-Registration
Table 20: OA Therapeutics - Phase III Pipeline
Table 21: OA Therapeutics - Phase II/III Pipeline
Table 22: OA Therapeutics - Phase II Pipeline
Table 23: OA Therapeutics - Phase I/II Pipeline
Table 24: OA Therapeutics - Phase I Pipeline
Table 25: OA Therapeutics - Preclinical Pipeline
Table 26: OA Therapeutics - Discovery Pipeline
Table 27: Other Mechanisms of Action from Figure 29
Table 28: OA Therapeutics - Promising Drugs Under Clinical Development, 2011
Table 29: OA Therapeutics - Clinical Trials by Country, 2011
Table 30: OA Therapeutics - Clinical Trials by Phase, 2011
Table 31: OA Therapeutics - Clinical Trials by Status, 2011
Table 32: OA Therapeutics, Overall Sponsors, 2011
Table 33: OA Therapeutics - Prominent Sponsors, 2011
Table 34: OA Therapeutics - Top Companies Participating in Clinical Trials, 2011
Table 35: BioDelivery Sciences International - Osteoarthritis Therapeutics Pipeline
Table 36: Cephalon, Inc. - Osteoarthritis Therapeutics Pipeline
Table 37: Iroko Pharmaceuticals, LLC - Osteoarthritis Therapeutics Pipeline
Table 38: Novartis AG - Osteoarthritis Therapeutics Pipeline
Table 39: SantoSolve AS - Osteoarthritis Therapeutics Pipeline
Table 40: Winston Pharmaceuticals, Inc. - Osteoarthritis Therapeutics Pipeline
Table 41: OA Therapeutics Market- Future Players
Table 42: OA Therapeutics - Licensing and Partnership Deals
1.2 List of Figures
Figure 1: Aetiology and Pathophysiology of Osteoarthritis
Figure 2: Articular Structures Affected in Osteoarthritis
Figure 3: OA Treatment Overview
Figure 4: OA Therapeutics Market, Major Markets, Revenue ($bn), 2005 - 2010
Figure 5: OA Therapeutics, Market Share ($m), 2010
Figure 6: OA Therapeutics Market, Major Markets, Forecast ($bn), 2010 - 2018
Figure 7: OA Therapeutics, Market Share ($m), 2018
Figure 8: OA Therapeutics Market, The US, Revenue ($bn), 2005 - 2010
Figure 9: OA Therapeutics Market, The US, Forecast ($bn), 2010 - 2018
Figure 10: OA Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Figure 11: OA Therapeutics Market, The UK, Forecast ($m), 2010 - 2018
Figure 12: OA Therapeutics Market, France, Revenue ($m), 2005 - 2010
Figure 13: OA Therapeutics Market, France, Forecast ($m), 2010 - 2018
Figure 14: OA Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Figure 15: OA Therapeutics Market, Germany, Forecast ($m), 2010 - 2018
Figure 16: OA Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Figure 17: OA Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Figure 18: OA Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Figure 19: OA Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Figure 20: OA Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Figure 21: OA Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Figure 22: OA Therapeutics Market, Drivers and Restraints 2011
Figure 23: Opportunity and Unmet Need in the OA Therapeutics Market, 2011
Figure 24: OA Therapeutics - Strategic Competitor Assessment, 2011
Figure 25: OA Therapeutics - Pipeline by Phase of Clinical Development, 2011
Figure 26: OA Therapeutics Pipeline - DMOAD versus Symptomatic Relief, 2011
Figure 27: OA Market - Clinical Pipeline by Mechanism of Action, 2011
Figure 28: Technology Trends Analytical Framework of the OA Pipeline, 2011
Figure 29: Technology Trends Analytical Framework of the OA Pipeline - Description, 2011
Figure 30: OA Therapeutics - Clinical Trials by Country, 2011
Figure 31: OA Therapeutics - Clinical Trials by Phase, 2011
Figure 32: OA Therapeutics - Clinical Trials by Status, 2011
Figure 33: OA Therapeutics - Overall Sponsors, 2011
Figure 34: OA Therapeutics - Prominent Sponsors, 2011
Figure 35: OA Therapeutic Clinical Trial - Company Sponsors by Phase, 2011
Figure 36: Implications for Future Market Competition in the Osteoarthritis Therapeutics Market, 2011
Figure 37: OA Therapeutics Market - Clinical Pipeline by Company , 2011
Figure 38: GlobalData Market Forecasting Model

Abstract

Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Osteoarthritis (OA) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global osteoarthritis therapeutics market. The report identifies the key trends shaping and driving the global osteoarthritis therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteoarthritis therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData estimates that the global OA therapeutics market was worth $4.4 billion in 2010 and forecasts it to grow at a compound annual growth rate (CAGR) of 3.8% to reach $5.9 billion by 2018. The current treatment options for OA offer only symptomatic relief and are primarily dominated by generics. There are no disease modifying osteoarthritis drugs (DMOAD) currently approved in the OA therapeutics market and the late stage pipeline also lacks DMOADs except SMC021. Owing to all the above factors the OA therapeutics market is expected to show slow growth till 2018.

Scope

The report provides information on the key drivers and challenges of the osteoarthritis therapeutics market. Its scope includes -
  • Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) osteoarthritis therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018.
  • Pipeline analysis data providing analysis of the different phases of development, mechanisms of action and emerging trends. Pipeline candidates for osteoarthritis fall under major therapeutic classes such as stem cell therapy, cyclooxygenase (COX) inhibitor, cathepsin inhibitors, opioid receptor agonist, anti-nerve growth factor (NGF) inhibitor, transient receptor potential vanilloid-1 (TRPV-1) antagonists, cyclooxygenase inhibiting nitric oxide donor, phosphodiesterase inhibitor and calcitonin receptor agonist.
  • Analysis of current and future competition in the global osteoarthritis market is provided. Key market players covered are BioDelivery Sciences International, Cephalon Inc, Iroko Pharmaceuticals, LLC, Novartis AG, SantoSolve AS and Winston Pharmaceuticals, Inc.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the osteoarthritis therapeutics market.
  • Analysis of key recent licensing and partnership agreements in osteoarthritis therapeutics market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global osteoarthritis therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global osteoarthritis therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global osteoarthritis therapeutics market landscape? - Identify, understand and capitalize.


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.